Case Study: Holotomography Reveals Insights into Chemotherapy Response of Heterogeneous Breast Cancer Patient Derived Tumoroids

Patient-derived organoids are valuable tools for precision oncology, but conventional endpoint assays cannot capture real-time drug response dynamics or the influence of stromal composition. This case study integrates Okomera's microfluidic organoid platform with Tomocube HT-X1™ Plus to enable label-free, time-lapse monitoring of breast cancer biopsy-derived organoids during chemotherapy treatment. HT's refractive index-based measurements provide a window into tumor-stroma heterogeneity and drug sensitivity without requiring additional staining.

What's inside

- High-throughput organoid generation from a single patient biopsy (234 organoids from 203 mg Luminal B breast tumor) using Okomera microfluidic chips

- Label-free HT time-lapse (72 h) tracking of organoid volume and granularity during carboplatin treatment

- Correlative HT and immunofluorescence distinguishing tumor (CK8+/CK5+) from stromal compartments by RI-based granularity

- Drug response profiling (IC50, AUC, Hill coefficient) correlated with stromal composition using granularity as a biophysical biomarker

Keywords

patient-derived organoid PDO drug screening breast cancer organoid holotomography label-free imaging carboplatin tumor microenvironment microfluidic organoid precision oncology HT-X1 Plus TomoAnalysis stromal cells time-lapse imaging 3D tumor model refractive index tomography

Download the Application Note

First name*

Last name*

Title

Company*

Region*

Country*

Interested Product*

E-mail*

Comment

I have read and agree to the Terms and Policies.